Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can engineered cells beat blood cancers that Won't quit?

NCT ID NCT07802756

Disease control Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 09, 2026 · Updated 3 times

Summary

This early-phase trial tests an experimental cell therapy called iMagic Injection in adults with relapsed or refractory blood cancers, specifically B-cell non-Hodgkin lymphoma and multiple myeloma. Participants receive a single infusion of engineered immune cells designed to attack their cancer. Researchers monitor safety, how long the cells last in the body, and whether tumors shrink over 24 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
iMagic Injection (IMV101 for lymphoma, IMV102 for myeloma), a type of cell therapy using CAR-T cells
What this could lead to
If it works, this could offer a new treatment option for people with blood cancers that have not responded to standard therapies.
What could go wrong
This is a very early, small study focused on safety, so the treatment may not work or could cause severe side effects. Success in this phase does not guarantee broader benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants voluntarily participate in clinical studies; Fully informed of this study and signed informed consent; Informed consent form must be obtained prior to initiation of any study-related tests or procedures that are not part of the standard treatment for the subject's disease; Good compliance and cooperation with follow-up. 2. 18\~80 years old. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4. With evaluable tumor lesion. 5. Relapsed and/or refractory hematologic malignancies (Non-Hodgkin Lymphoma or Multiple Myeloma). 6. Life expectancy≥ 3 months. 7. Clinical laboratory values meet screening visit criteria. 8. Adequate organ function. Exclusion Criteria: 1. Participants cannot have ongoing acute systemic infection requiring antimicrobial therapy. 2. Prior antitumor therapy with insufficient washout period. 3. Known life-threatening allergic reaction, hypersensitivity reaction, or intolerance to study drug excipients and related excipients, including but not limited to DMSO; or those with a history of severe allergic reactions in the past (such as hypersensitivity reactions, or those with severe immune-related reactions such as the need for glucocorticoids to prevent anaphylaxis as assessed by the investigator). 4. Lactating women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Relapsed/refractory B-cell non-Hodgkin lymphoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma hematopoietic and lymphoid system neoplasm plasma cell myeloma refractory hematologic cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Relapsed/refractory hematologic malignancies

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.